Complications: tracking down the data on oseltamivir

BMJ 2009; 339 doi: (Published 8 December 2009)
Cite this as: BMJ 2009;339:b5387

Related articles

Analysis: Multisystem failure: the story of anti-influenza drugs

Editorial: The Tamiflu trials

Feature: Oseltamivir: another case of regulatory failure?

Analysis: Restoring invisible and abandoned trials: a call for people to publish the findings

Observations: Withdraw approval for Tamiflu until NICE has full data

Observations: Open letter to Roche about oseltamivir trial data

Letter: Time for change, WHO

Feature: WHO and the pandemic flu “conspiracies”

Correction: Complications: tracking down the data on oseltamivir

Editor's Choice: We want raw data, now

Research: Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis

Analysis: Neuraminidase inhibitors—the story behind the Cochrane review

Letter: Point-by-point response from Roche to BMJ questions

Editorial: Why don’t we have all the evidence on oseltamivir?

Analysis: What can we learn from observational studies of oseltamivir to treat influenza in healthy adults?

Letter: Roche replies to the authors of the Cochrane Review on oseltamivir

Research: Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials

Data supplement

Web Extra

Web Extra

This article has been cited by other articles: